Solventum (NYSE:SOLV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Solventum (NYSE:SOLV) from a hold rating to a buy rating in a report released on Saturday.

Several other brokerages have also weighed in on SOLV. Zacks Research lowered shares of Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. Jefferies Financial Group started coverage on shares of Solventum in a research note on Thursday, September 11th. They set a “hold” rating and a $80.00 price target on the stock. Piper Sandler upped their target price on Solventum from $94.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. UBS Group reaffirmed a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. Finally, BTIG Research upgraded Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Tuesday, December 2nd. Four analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $87.00.

Solventum Trading Down 1.3%

NYSE:SOLV opened at $81.87 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03. The firm has a market cap of $14.20 billion, a P/E ratio of 9.43, a PEG ratio of 8.76 and a beta of 0.26. The stock’s 50 day simple moving average is $76.12 and its 200-day simple moving average is $74.48. Solventum has a 12-month low of $60.70 and a 12-month high of $88.20.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The business had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. During the same quarter in the previous year, the firm earned $1.64 earnings per share. The business’s quarterly revenue was up .7% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Equities analysts anticipate that Solventum will post 6.58 EPS for the current year.

Solventum declared that its board has initiated a share repurchase plan on Thursday, November 20th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to buy up to 7.5% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its shares are undervalued.

Institutional Investors Weigh In On Solventum

Institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP lifted its stake in Solventum by 2.8% during the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after purchasing an additional 129 shares during the last quarter. Swiss Life Asset Management Ltd raised its position in Solventum by 26.1% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 27,504 shares of the company’s stock valued at $2,008,000 after purchasing an additional 5,686 shares during the last quarter. CIBC Private Wealth Group LLC lifted its stake in Solventum by 0.5% in the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock worth $1,804,000 after acquiring an additional 134 shares during the period. CIBC Bancorp USA Inc. bought a new stake in shares of Solventum during the 3rd quarter valued at about $1,506,000. Finally, Maven Securities LTD bought a new position in shares of Solventum in the 3rd quarter worth approximately $912,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.